BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21937974)

  • 1. FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Sep; 60(37):1279-80. PubMed ID: 21937974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Apr; 58(14):374-5. PubMed ID: 19373199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Jun; 61(25):468-70. PubMed ID: 22739778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Murphy TV; Slade BA; Broder KR; Kretsinger K; Tiwari T; Joyce PM; Iskander JK; Brown K; Moran JS;
    MMWR Recomm Rep; 2008 May; 57(RR-4):1-51. PubMed ID: 18509304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Jan; 60(1):13-5. PubMed ID: 21228763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US.
    Plosker GL
    BioDrugs; 2009; 23(4):253-67. PubMed ID: 19697967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tdap vaccine: current indications for adolescent and adult patients in the United States.
    Kirchner JT
    J Am Osteopath Assoc; 2011 Oct; 111(10 Suppl 6):S7-9. PubMed ID: 22086895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.
    Kretsinger K; Broder KR; Cortese MM; Joyce MP; Ortega-Sanchez I; Lee GM; Tiwari T; Cohn AC; Slade BA; Iskander JK; Mijalski CM; Brown KH; Murphy TV; ; ;
    MMWR Recomm Rep; 2006 Dec; 55(RR-17):1-37. PubMed ID: 17167397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials.
    Van Damme P; McIntyre P; Grimprel E; Kuriyakose S; Jacquet JM; Hardt K; Messier M; Van Der Meeren O
    Vaccine; 2011 Aug; 29(35):5932-9. PubMed ID: 21718738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Liang JL; Tiwari T; Moro P; Messonnier NE; Reingold A; Sawyer M; Clark TA
    MMWR Recomm Rep; 2018 Apr; 67(2):1-44. PubMed ID: 29702631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
    Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
    Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months --- Advisory Committee on Immunization Practices (ACIP), 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(41):1424-6. PubMed ID: 22012116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
    Weston WM; Friedland LR; Wu X; Howe B
    Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Notes from the field : use of tetanus, diphtheria, and pertussis vaccine (Tdap) in an Emergency Department - Arizona, 2009-2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Jan; 61(3):55-6. PubMed ID: 22278160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation.
    Small TN; Zelenetz AD; Noy A; Rice RD; Trippett TM; Abrey L; Portlock CS; McCullagh EJ; Vanak JM; Mulligan AM; Moskowitz CH
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1538-42. PubMed ID: 19896077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine.
    Weston W; Messier M; Friedland LR; Wu X; Howe B
    Vaccine; 2011 Nov; 29(47):8483-6. PubMed ID: 21945698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetanus and pertussis vaccination coverage among adults aged ≥ 18 years --- United States, 1999 and 2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Oct; 59(40):1302-6. PubMed ID: 20948508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.